CARD17P: A Potential Drug Target and Biomarker (G440068)

Target Name: CARD17P

NCBI ID: G440068

CARD17P

CARD17P: A Potential Drug Target and Biomarker

CARD17P, also known as cardiopulmonary exercise-induced angiogenesis (CPE-A) or cardiomyopathy-associated protein 17, is a protein that is expressed in the hearts of individuals with cardiomyopathy, a condition in which the heart muscle becomes weakened or does not function properly. Cardiomyopathy can be caused by a variety of factors, including genetic, physical, and environmental factors.

Recent studies have identified CARD17P as a potential drug target and biomarker for the treatment of cardiomyopathy. By blocking the activity of CARD17P, researchers have found that they can improve heart function and reduce the risk of cardiac complications in individuals with cardiomyopathy.

One of the reasons for the potential of CARD17P as a drug target is its involvement in the development and progression of cardiomyopathy. Studies have shown that CARD17P is expressed in the hearts of individuals with various forms of cardiomyopathy, including dilated cardiomyopathy, or left ventricular hypertrophy (LVH), which is a common complication in cardiomyopathy.

Additionally, CARD17P has been shown to play a role in the regulation of cell signaling pathways that are involved in the development and progression of cardiomyopathy. For example, studies have shown that CARD17P can inhibit the activity of the protein PDGF-BB, which is involved in the development of LVH.

Another potential mechanism by which CARD17P may contribute to the development and progression of cardiomyopathy is its role in the regulation of the immune response. Studies have shown that CARD17P is involved in the regulation of immune cell function and that its expression is influenced by factors such as stress and inflammation.

In addition to its potential role as a drug target, CARD17P has also been identified as a potential biomarker for the diagnosis and monitoring of cardiomyopathy. Studies have shown that the expression of CARD17P is significantly increased in the hearts of individuals with cardiomyopathy compared to the hearts of individuals without cardiomyopathy. Additionally, CARD17P has been shown to be a reliable biomarker for the prediction of outcomes in individuals with cardiomyopathy, such as the risk of cardiac death or the need for cardiac transplantation.

Overall, the potential of CARD17P as a drug target and biomarker for the treatment of cardiomyopathy is significant. Further research is needed to fully understand its role in the development and progression of cardiomyopathy and to determine the most effective way to use it as a treatment. However, the studies that have been conducted so far suggest that CARD17P may be a promising target for the development of new treatments for cardiomyopathy.

Protein Name: Caspase Recruitment Domain Family Member 17, Pseudogene

Functions: Regulator of procaspase-1/CASP1 activation implicated in the regulation of the proteolytic maturation of pro-IL-1beta/IL1B and its release during inflammation. Inhibits the release of IL1B in response to LPS in monocytes. However, unlike CASP1, do not induce NF-kappa-B activation

The "CARD17P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CARD17P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets